Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

“In mild cases it can be managed with moisturisers ... are more likely to develop atopic dermatitis. It is the most common ...

Eczema symptoms can be mild — a small patch of itchy, dry, red or pink textured skin — or they can be severe, Dr. Shasa Hu, ...

Atopic dermatitis, which many people call eczema ... or topical hydrocortisone, can help relieve mild symptoms. Doctors may also prescribe topical medications to treat small areas.

Atopic dermatitis (AD) is a skin disease of chronic inflammation exacerbated by acute flares that commonly affects infants, children, and adults. Therapies generally include emollients ...

“Topical therapies remain a cornerstone for treating atopic dermatitis (AD) whether patients have mild, moderate or severe disease. But there remains an unmet need for safe, effective and ...

Patients with atopic dermatitis (N=813 ... the median time to first worsening (defined as vIGA-AD ≥2 [mild]) was 57 days (95% CI, 30-79). The most common adverse reactions reported with ...

Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

today for treating patients with atopic dermatitis (AD) aged 2 and older. 1 Tapinarof cream 1% was previously approved in 2022 to treat adult patients with mild, moderate, and severe plaque psoriasis.

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...